Showing 2541-2550 of 3039 results for "".
- Heru Announces Commercial Availability of re:Vive in Partnership With Vision Sourcehttps://modernod.com/news/heru-launches-commercial-availability-of-revive-in-partnership-with-vision-source/2479437/Heru announced, in partnership with its worldwide launch partner Vision Source, the commercial availability of re:Vive, its wearable diagnostics and visual field application. re:Vive by Heru is a wearable porta
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- Nickelodeon and OneSight Team Up for Kids Eye Health Campaignhttps://modernod.com/news/nickelodeon-and-onesight-team-up-for-kids-eye-health-campaign/2479424/More than 230 million kids around the world under the age of 15 lack access to the glasses they need. To make a positive impact on kids’ eye health globally, Nickelodeon International’s “Together for Good” and OneSight, a global vision nonprofit, announced their partnership on a new, multi-territ
- Modernizing Medicine Showcases Single-Screen Innovations at ASCRShttps://modernod.com/news/modernizing-medicine-showcases-single-screen-innovations-at-ascrs/2479405/Modernizing Medicine announced it has enhanced its electronic health records (EHR), EMA with functionality that can help to speed up documentation by removing steps in note-taking and allowing for quick editing, importing charts and more. These new and improved workflows for clinical docu
- Ocuphire Announces Publication Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Diseasehttps://modernod.com/news/ocuphire-announces-publication-featuring-its-oral-ref-1-inhibitor-apx3330-in-phase-2-trial-for-the-treatment-of-retinal-disease/2479396/Ocuphire Pharma announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled “APE1/Ref-1 as a Novel Target for Retinal Disease.” The Journal of Cellula
- Iveric Bio Appoints Christopher Simms as Chief Commercial Officerhttps://modernod.com/news/iveric-bio-appoints-christopher-simms-as-chief-commercial-officer/2479390/Iveric bio announced the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he managed commercial operations for the U.S. Ophthalmics Franchise, launching Beovu (brolucizumab inje
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479335/Nicox SA announced that the last patient in the NCX 4251 Mississippi phase 2b blepharitis clinical trial has now completed the 2-week treatment phase as well as the required 2-week follow up period. Topline results are expected to be announced in September 20
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom